0M0F.L - Tandem Diabetes Care, Inc.
Chart Events
Performance Outlook
- Short Term2W - 6W
- Mid Term6W - 9M
- Long Term9M+
| Previous Close | 24.64 |
| Open | 0.00 |
| Bid | 0.00 x N/A |
| Ask | 0.00 x N/A |
| Day's Range | 0.00 - 0.00 |
| 52 Week Range | |
| Volume | |
| Avg. Volume | 303 |
| Market Cap | 14.147M |
| Beta (5Y Monthly) | 0.97 |
| PE Ratio (TTM) | 2.81 |
| EPS (TTM) | N/A |
| Earnings Date | N/A |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
Fair Value
Related Research
- Business Wire
Tandem Diabetes Care to Present at the Jefferies Healthcare Conference
SAN DIEGO, May 24, 2023--Tandem Diabetes Care, Inc. (NASDAQ: TNDM), a leading insulin delivery and diabetes technology company, today announced that management will present a company update at the Jefferies Healthcare Conference on Thursday, June 8, 2023 at 1:30pm Eastern Time (10:30am Pacific Time).
- Business Wire
Tandem Diabetes Care Announces First Quarter 2023 Financial Results and Reaffirms Full Year 2023 Financial Guidance
SAN DIEGO, May 03, 2023--Tandem Diabetes Care, Inc. (NASDAQ: TNDM), a global insulin delivery and diabetes technology company, today reported its financial results for the quarter ended March 31, 2023 and reaffirmed its financial guidance for the year ending December 31, 2023.
- Business Wire
Tandem Diabetes Care to Present at the BofA Securities 2023 Health Care Conference
SAN DIEGO, April 20, 2023--Tandem Diabetes Care, Inc. (NASDAQ: TNDM), a leading insulin delivery and diabetes technology company, today announced that management will present a company update at the BofA Securities 2023 Health Care Conference on Wednesday, May 10, 2023 at 4:40pm Eastern Time (1:40pm Pacific Time).
- Business Wire
Tandem Diabetes Care Announces Control-IQ Technology Meta-analysis Demonstrating Positive Clinical Impact of Automatic Correction Bolusing on Glucose Control in People with Type 1 Diabetes
SAN DIEGO, April 17, 2023--Tandem Diabetes Care, Inc. (NASDAQ: TNDM), a leading insulin delivery and diabetes technology company, today announced publication by Diabetes Technology & Therapeutics of a meta-analysis of three randomized controlled trials of its Control-IQ advanced hybrid closed-loop technology. Results demonstrate the positive clinical impact of the system’s automatic correction bolusing on glucose control across a wide range of ages and demographics of people living with type 1 d
- Business Wire
Tandem Diabetes Care to Announce First Quarter 2023 Financial Results on May 3, 2023
SAN DIEGO, April 11, 2023--Tandem Diabetes Care, Inc. (NASDAQ: TNDM), a leading insulin delivery and diabetes technology company, plans to release its first quarter 2023 results after the financial markets close on Wednesday, May 3, 2023. The Company will hold a conference call and simultaneous webcast on the same day at 4:30 pm Eastern Time (1:30 pm Pacific Time), to discuss its first quarter 2023 financial and operating results.
- Business Wire
Tandem Diabetes Care Announces NEJM Publication of Study Demonstrating Increased Time in Range in Young Children with Type 1 Diabetes Using the t:slim X2 Insulin Pump with Control-IQ Technology
SAN DIEGO, March 15, 2023--Tandem Diabetes Care, Inc. (NASDAQ: TNDM), a leading insulin delivery and diabetes technology company, today announced publication of results from the Pediatric Artificial Pancreas (PEDAP) Clinical Trial by the New England Journal of Medicine showing an approximate 3-hour per day increase in time in range* in children ages 2-5 years old using the t:slim X2 insulin pump with Control-IQ advanced hybrid closed-loop technology** compared to those on a standard insulin pump
- PR Newswire
Fair Isaac & Co. Set to Join S&P 500; Others to Join S&P MidCap 400 and S&P SmallCap 600
S&P Dow Jones Indices ("S&P DJI") will make the following changes to the S&P 500, S&P MidCap 400 and S&P SmallCap 600 indices effective prior to the open of trading on Monday, March 20, to coincide with the quarterly rebalance. The changes are being made to ensure each index is more representative of its market capitalization range. The company moving to the S&P 500 is more representative of the large-cap market space. All companies moving to the S&P MidCap 400 are more representative of the mid
- Business Wire
Tandem Diabetes Care Appoints New Chair of Board of Directors
SAN DIEGO, February 22, 2023--Tandem Diabetes Care, Inc. (NASDAQ: TNDM), a leading insulin delivery and diabetes technology company, today announced the appointment of Rebecca Robertson as Chair of its Board of Directors. Ms. Robertson, who joined Tandem’s Board as an independent director in January 2019, succeeds Kim Blickenstaff, who will continue as a member of the Board.
- Business Wire
Tandem Diabetes Care Announces Fourth Quarter 2022 Financial Results and Full Year 2023 Financial Guidance
SAN DIEGO, February 22, 2023--Tandem Diabetes Care, Inc. (NASDAQ: TNDM), a global insulin delivery and diabetes technology company, today reported its financial results for the quarter and year ended December 31, 2022 and provided its financial guidance for the year ending December 31, 2023.
- Business Wire
Tandem Diabetes Care Announces Upcoming Conference Presentations
SAN DIEGO, February 15, 2023--Tandem Diabetes Care, Inc. (NASDAQ: TNDM), a leading insulin delivery and diabetes technology company, today announced that management will present a company update at the following investor conferences:
- Business Wire
Tandem Diabetes Care Completes Acquisition of Insulin Patch Pump Developer, AMF Medical
SAN DIEGO, January 23, 2023--Tandem Diabetes Care, Inc. (NASDAQ:TNDM), a global insulin delivery and diabetes technology company, today announced the completion of its previously announced acquisition of AMF Medical SA, the privately held Swiss developer of the Sigi™ Patch Pump. The Sigi Patch Pump, designed to be an ergonomic, rechargeable patch pump that reduces the burden of managing diabetes through its use of pre-filled insulin cartridges, is under development and not commercially available
- Business Wire
Tandem Diabetes Care to Announce Fourth Quarter and Full Year 2022 Financial Results on February 22, 2023
SAN DIEGO, January 19, 2023--Tandem Diabetes Care, Inc. (NASDAQ: TNDM), a leading insulin delivery and diabetes technology company, plans to release its fourth quarter and full year 2022 results after the financial markets close on Wednesday, February 22, 2023. The Company will hold a conference call and simultaneous webcast on the same day at 4:30 pm Eastern Time (1:30 pm Pacific Time), to discuss its fourth quarter and full year 2022 financial and operating results.
- Business Wire
Tandem Diabetes Care Reports Preliminary, Unaudited 2022 Sales and Reaffirms 2023 Outlook
SAN DIEGO, January 10, 2023--Tandem Diabetes Care, Inc. (NASDAQ: TNDM), a global insulin delivery and diabetes technology company, today reported its preliminary, unaudited sales for the fourth quarter and year ended December 31, 2022 and worldwide sales outlook for the year ending December 31, 2023.
- Business Wire
Tandem Diabetes Care to Present at the 41st Annual J.P. Morgan Healthcare Conference
SAN DIEGO, January 03, 2023--Tandem Diabetes Care, Inc. (NASDAQ: TNDM), a leading insulin delivery and diabetes technology company, today announced that management will present a company update at the 41st Annual J.P. Morgan Healthcare Conference on Wednesday, January 11, 2023 at 8:15pm Eastern Time (5:15pm Pacific Time).
- Business Wire
Tandem Diabetes Care to Acquire Insulin Patch Pump Developer, AMF Medical
SAN DIEGO, December 13, 2022--Tandem Diabetes Care, Inc. (NASDAQ:TNDM), a global insulin delivery and diabetes technology company, today announced that it has entered into a definitive agreement to acquire AMF Medical SA, the privately held Swiss developer of the Sigi™ Patch Pump. The Sigi Patch Pump is under development and not commercially available. It is designed to be an ergonomic, rechargeable patch pump that reduces the burden of managing diabetes through its use of pre-filled insulin car
- Business Wire
Tandem Diabetes Care Earns Great Place to Work Certification™
SAN DIEGO, November 16, 2022--Tandem Diabetes Care, Inc. (NASDAQ:TNDM), a global insulin delivery and diabetes technology company, is proud to announce its Great Place to Work Certification™, a prestigious award based entirely on results from in-depth employee surveys around their experience working at the company. This year, 84 percent of Tandem employees said it’s a great place to work – 27 points higher than the average participating company in the United States.
- Business Wire
Tandem Diabetes Care Study Demonstrates Improvements of All Clinical Endpoints in Adults with Type 2 Diabetes Using Control-IQ Technology
SAN DIEGO, November 10, 2022--Tandem Diabetes Care, Inc. (NASDAQ: TNDM), a leading insulin delivery and diabetes technology company, announced results from a prospective, multicenter, single-arm study of adults living with type 2 diabetes who achieved improvement in all clinical endpoints with the use of the t:slim X2 insulin pump with Control-IQ technology.1
- Business Wire
Tandem Diabetes Care Announces Upcoming Conference Presentation
SAN DIEGO, November 08, 2022--Tandem Diabetes Care, Inc. (NASDAQ: TNDM), a leading insulin delivery and diabetes technology company, today announced that management will present a company update at the Piper Sandler 34th Annual Healthcare Conference on Wednesday, November 30, 2022 at 9:00am Eastern Time (6:00am Pacific Time).
- Business Wire
Tandem Diabetes Care Announces Third Quarter 2022 Financial Results and Updated Full Year 2022 Financial Guidance
SAN DIEGO, November 02, 2022--Tandem Diabetes Care, Inc. (NASDAQ: TNDM), a global insulin delivery and diabetes technology company, today reported its financial results for the quarter ended September 30, 2022 and updated its financial guidance for the year ending December 31, 2022.
- Business Wire
Tandem Diabetes Care to Announce Third Quarter 2022 Financial Results on November 2, 2022
SAN DIEGO, October 04, 2022--Tandem Diabetes Care, Inc. (NASDAQ: TNDM), a leading insulin delivery and diabetes technology company, plans to release its third quarter 2022 results after the financial markets close on Wednesday, November 2, 2022. The Company will hold a conference call and simultaneous webcast on the same day at 4:30 pm Eastern Time (1:30 pm Pacific Time), to discuss its third quarter 2022 financial and operating results.
- GlobeNewswire
Parexel Appoints Peyton Howell Chief Operating and Growth Officer; Promotes FDA Veteran Amy McKee, MD, to Chief Medical Officer and Global Head, Oncology Center of Excellence
Key leadership appointments focused on enhancing connections and collaboration to drive Innovation across the next-generation delivery of clinical trials and fuel more integrated, therapeutically-focused solutions for patientsBOSTON and DURHAM, N.C., Sept. 14, 2022 (GLOBE NEWSWIRE) -- Parexel, a leading global clinical research organization (CRO), today announced the promotions of Peyton Howell to the newly-created role of Chief Operating and Growth Officer and Amy McKee, MD, to Chief Medical Of
- Business Wire
Tandem Diabetes Care Achieves Milestone of 1 Million Insulin Boluses Delivered Using Its t:connect Mobile App
SAN DIEGO, August 18, 2022--Tandem Diabetes Care, Inc. (NASDAQ:TNDM), a leading insulin delivery and diabetes technology company, today announced that t:slim X2 insulin pump users have delivered more than 1 million insulin boluses using the t:connect app feature on their personal mobile device in the first month following its commercial release.
- Business Wire
Tandem Diabetes Care Announces Second Quarter 2022 Financial Results and Updated Full Year 2022 Financial Guidance
SAN DIEGO, August 03, 2022--Tandem Diabetes Care, Inc. (NASDAQ: TNDM), a global insulin delivery and diabetes technology company, today reported its financial results for the quarter ended June 30, 2022 and updated its financial guidance for the year ending December 31, 2022.
- Business Wire
Tandem Diabetes Care Acquires Infusion Set Developer, Capillary Biomedical
SAN DIEGO, July 21, 2022--Tandem Diabetes Care, Inc. (NASDAQ:TNDM), a global insulin delivery and diabetes technology company, today announced its acquisition of infusion set developer, Capillary Biomedical.
- Business Wire
Tandem Diabetes Care to Announce Second Quarter 2022 Financial Results on August 3, 2022
SAN DIEGO, July 12, 2022--Tandem Diabetes Care, Inc. (NASDAQ: TNDM), a leading insulin delivery and diabetes technology company, plans to release its second quarter 2022 results after the financial markets close on Wednesday, August 3, 2022. The Company will hold a conference call and simultaneous webcast on the same day at 4:30 pm Eastern Time (1:30 pm Pacific Time), to discuss its second quarter 2022 financial and operating results.
